Regulatory Science

Botanical INDs present unique challenges in chemistry, manufacturing, and controls (CMC) and quality assurance that distinguish them from conventional single-molecule drug development. Over more than two decades, the FDA has progressively constructed a fit-for-purpose regulatory pathway through two successive guidance documents (2004, 2016), the establishment of a dedicated Botanical Review Team within CDER, and the review of hundreds of...